KURA ONCOLOGY DL-,0001 WKN: A143UH ISIN: US50127T1097 Kürzel: KUR Forum: Aktien Thema: Hauptdiskussion

Der CEO kaufte diese Woche 50.000 Aktien zu 6,06$

November wird spannend.

jetzt steigt es wieder gut, weiß jemand mehr ?

Die Investoren haben sich wohl mehr erhofft gestern ? so wie der Kurs nach unten geht

https://finance.yahoo.com/news/kura-oncology-reports-second-quarter-200500029.html

🧪

👀

Reuters Kura Oncology to partner with Kyowa Kirin for blood cancer therapy Nov 20, 2024 at 10:36 pm GMT

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

🎈

So machen Kapitalerhöhungen Spass... https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-announces-oversubscribed-150-million-private

$KURA Announces Financing Transactions with $BMY and Hercules Capital, Providing Access to up to $150M. $25M equity investment from $BMY at $18.25/share

Kura Oncology Reports Second Quarter 2021 Financial Results https://www.globenewswire.com/news-release/2021/08/05/2276004/35186/en/Kura-Oncology-Reports-Second-Quarter-2021-Financial-Results.html – First patients dosed in Phase 1b expansion cohorts with menin inhibitor KO-539 – – Clinical collaboration with Novartis to evaluate tipifarnib in combination with the PI3Kα inhibitor alpelisib in HNSCC – – KO-2806 nominated as lead development candidate in next-generation farnesyl transferase inhibitor program – – $567.5 million in cash, cash equivalents and investments provide runway into 2024 – ...

Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma https://www.gurufocus.com/news/1468895/kura-oncology-announces-clinical-collaboration-to-evaluate-tipifarnib-in-combination-with-alpelisib-in-head-and-neck-squamous-cell-carcinoma

Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539 https://www.globenewswire.com/news-release/2021/06/24/2252605/35186/en/Kura-Oncology-Doses-First-Patient-in-Phase-1b-Expansion-Cohorts-with-Menin-Inhibitor-KO-539.html – Phase 1b expansion cohorts designed to enable refinement of recommended Phase 2 dose – – At least 12 patients to be enrolled in each of two Phase 1b expansion cohorts: a 200 mg dose cohort and a 600 mg dose cohort – – Each cohort to be genetically enriched with NPM1-mutant and KMT2A-rearranged relapsed/refractory AML patients – – Company anticipates that patient data from the recommended Phase 2 dose cohort will be included as part of the registration-directed portion of the trial –